phipps_matt_land

Matt Phipps

Analyst
+1 312 364 8602
Email vCard

Specialties:  Biotechnology

Matt Phipps, Ph.D., a biotechnology analyst, joined William Blair in November 2014, after working as a postdoctoral research fellow at Texas Scottish Rite Hospital for Children. Mr. Phipps earned a Ph.D. in cellular and molecular physiology from the University of Alabama at Birmingham and a B.S in physics in medicine from the University of Notre Dame.

Autolus Therapeutics plc: Initiation of Research Coverage

William Blair & Company initiated research coverage of Autolus Therapeutics plc (AUTL $20.86). Autolus, based in London, England, is developing next-generation genetically engineered immune cells, termed CAR-T therapies, with a broad pipeline designed to improve on the efficacy observed with the first wave of approved CAR-T therapies. Learn More

Kezar Life Sciences, Inc.: Initiation of Research Coverage

William Blair & Company initiated research coverage of Kezar Life Sciences, Inc. (KZR $16.50). Kezar Life Sciences is developing a novel small molecule inhibitor of the immunoproteasome, KZR-616, which has demonstrated a unique mechanism of action to regulate autoimmunity. Learn More

Pieris Pharmaceuticals, Inc.: Initiation of Research Coverage

William Blair & Company initiated research coverage of Pieris Pharmaceuticals, Inc. (PIRS $7.46), a clinical-stage biotech company developing novel therapies using the company’s proprietary Anticalin platform. Learn More